ESMO Congress 2024
Sep 13, 2024 · Promising antitumour activity presented for emerging targets in different solid tumours. Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology. Adjuvant immunotherapy continues to confirm its efficacy in melanoma.
From Practice-Changing Data to Future Innovation, Patient Outcome
Date: 13 Sep 2024. Studies presented at the ESMO Congress 2024 bring immunotherapy into new disease areas with high unmet need. Novel agents and technologies show promise in various indications and offer a glimpse into the future of oncology.
ESMO 2024 Press Conference
Sep 13, 2024 · The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.
ESMO Congress 2024 - Daily Reporter
Promising antitumour activity presented for emerging targets in different solid tumours. Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology. 16 Sept 2024. Cancer Research.
Breast Cancer Breakthroughs: 2024 ESMO Highlights
Oct 21, 2024 · The incredible pace of advancements in breast cancer therapeutics was again demonstrated at the 2024 European Society for Medical Oncology (ESMO) Congress. At the forefront of these advances were new data for several antibody-drug conjugates (ADCs) and molecular therapeutics.
Latest News - ESMO Daily Reporter
Molecular Oncology. Data from molecular analyses unveil diverse resistance mechanisms to endocrine therapy in breast cancer. Among the presented findings, a potential role for ESR1 gene fusions was observed. 16 Oct 2024. Melanoma. Adjuvant immunotherapy continues to confirm its efficacy in melanoma.
Promising antitumour activity for emerging targets - dailyreporter.esmo…
Sep 16, 2024 · At the ESMO Congress 2024 (Barcelona, 13–17 September), some early-phase trials described promising strategies to target emerging actionable mutations in different solid tumours, such as methylthioadenosine phosphorylase (MTAP) deletion, KRAS G12D mutation, and CDK4 and 2, reporting good tolerability and antitumour activity for novel targeted ...
ESMO 2024: For T-cell target antigens, lots to see, but what to …
Sep 16, 2024 · Metastatic solid tumors may be curable now. Among the most profound results presented over the weekend at the European Society for Medical Oncology (ESMO) 2024 Congress were the 10-year data from the Checkmate-067 and Keynote-006 trials, the phase III trials that tested Opdivo (nivolumab, Bristol Myers Squibb Co.) and Keytruda (pembrolizumab ...
ESMO Congress 2024: Five Days of Science Dissemination and …
Date: 18 Sep 2024. Bringing another annual reunion of the global oncology community to a resounding close, the 34,000 attendees of the ESMO Congress 2024 had the opportunity to gather around to listen to the most important results presented in …
ESMO 2024: breaking news and abstracts - Oncology Central
With ESMO 2024 (13–17 September, Barcelona, Spain) wrapped up, we're excited to bring you the latest breaking news, late-breaking abstracts and highlights from this year's congress. From groundbreaking trials to innovative research developments, this collection captures the most impactful moments.
- Some results have been removed